Association of BMI, lipid-lowering medication, and age with prevalence of type 2 diabetes in adults with heterozygous familial hypercholesterolaemia: a worldwide cross-sectional study
| Authors | |
|---|---|
| Year of publication | 2024 |
| Type | Article in Periodical |
| Magazine / Source | LANCET DIABETES & ENDOCRINOLOGY |
| MU Faculty or unit | |
| Citation | |
| web | https://www.thelancet.com/journals/landia/article/PIIS2213-8587%2824%2900221-3/fulltext |
| Doi | https://doi.org/10.1016/S2213-8587(24)00221-3 |
| Keywords | BMI; lipid-lowering medication; age; type 2 diabetes; heterozygous familial hypercholesterolaemia |
| Attached files | |
| Description | Background Statins are the cornerstone treatment for patients with heterozygous familial hypercholesterolaemia but research suggests it could increase the risk of type 2 diabetes in the general population. A low prevalence of type 2 diabetes was reported in some familial hypercholesterolaemia cohorts, raising the question of whether these patients are protected against type 2 diabetes. Obesity is a well known risk factor for the development of type 2 diabetes. We aimed to investigate the associations of known key determinants of type 2 diabetes with its prevalence in people with heterozygous familial hypercholesterolaemia. |
| Related projects: |